1
|
Desmercieres S, Lardeux V, Longueville JE, Dugast E, Thiriet N, Solinas M. Effects of Highly Palatable Diet on motivation for food and resistance to punishment in rats: Role of sex and age of exposure. Appetite 2024; 198:107340. [PMID: 38582135 DOI: 10.1016/j.appet.2024.107340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2023] [Revised: 03/05/2024] [Accepted: 04/03/2024] [Indexed: 04/08/2024]
Abstract
Exposure to highly palatable food is believed to induce behavioral and neurobiological changes that may produce addiction-like behavior and increase the risks of obesity and overweight. Studies in rodents have led to conflicting results suggesting that several factors such as sex and age of exposure contribute to the development of maladaptive behaviors towards food. In addition, it is not clear whether effects of exposure to highly palatable diets (HPD) persist after their discontinuation, which would indicate long-term risks to develop addiction-like behavior. In this study, we investigated the persistent effects of an intermittent 8-week exposure to HPD in male and female rats as a function of age of exposure (adult and adolescent). We found that intermittent exposure to HPD did not alter body weight, but it affected consumption of standard food during the time of exposure in all groups. In addition, in adults, HPD produced a decrease in the initial baseline responding in FR1 schedules, an effect that persisted for 4 weeks in males but not in female rats. However, we found that exposure to HPD did not affect resistance to punishment measured by progressive shock strength break points or motivation for food as measured by progressive-ratio break points regardless of sex or age of exposure. Altogether, these results do not provide support for the hypothesis that intermittent exposure to HPD produce persistent increases in the vulnerability to develop addiction-like behaviors towards palatable food.
Collapse
Affiliation(s)
- Stevenson Desmercieres
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
| | - Virginie Lardeux
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
| | - Jean-Emmanuel Longueville
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
| | - Emilie Dugast
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France; CHU de Poitiers, Poitiers, France
| | - Nathalie Thiriet
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
| | - Marcello Solinas
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France.
| |
Collapse
|
2
|
Boussamet L, Montassier E, Mathé C, Garcia A, Morille J, Shah S, Dugast E, Wiertlewski S, Gourdel M, Bang C, Stürner KH, Masson D, Nicot AB, Vince N, Laplaud DA, Feinstein DL, Berthelot L. Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study. Sci Rep 2024; 14:7786. [PMID: 38565581 PMCID: PMC10987558 DOI: 10.1038/s41598-024-57949-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Accepted: 03/23/2024] [Indexed: 04/04/2024] Open
Abstract
In multiple sclerosis (MS), alterations of the gut microbiota lead to inflammation. However, the role of other microbiomes in the body in MS has not been fully elucidated. In a pilot case-controlled study, we carried out simultaneous characterization of faecal and oral microbiota and conducted an in-depth analysis of bacterial alterations associated with MS. Using 16S rRNA sequencing and metabolic inference tools, we compared the oral/faecal microbiota and bacterial metabolism pathways in French MS patients (n = 14) and healthy volunteers (HV, n = 21). A classification model based on metabolite flux balance was established and validated in an independent German cohort (MS n = 12, HV n = 38). Our analysis revealed decreases in diversity indices and oral/faecal compartmentalization, the depletion of commensal bacteria (Aggregatibacter and Streptococcus in saliva and Coprobacter and Roseburia in faeces) and enrichment of inflammation-associated bacteria in MS patients (Leptotrichia and Fusobacterium in saliva and Enterobacteriaceae and Actinomyces in faeces). Several microbial pathways were also altered (the polyamine pathway and remodelling of bacterial surface antigens and energetic metabolism) while flux balance analysis revealed associated alterations in metabolite production in MS (nitrogen and nucleoside). Based on this analysis, we identified a specific oral metabolite signature in MS patients, that could discriminate MS patients from HV and rheumatoid arthritis patients. This signature allowed us to create and validate a discrimination model on an independent cohort, which reached a specificity of 92%. Overall, the oral and faecal microbiomes were altered in MS patients. This pilot study highlights the need to study the oral microbiota and oral health implications in patients with autoimmune diseases on a larger scale and suggests that knowledge of the salivary microbiome could help guide the identification of new pathogenic mechanisms associated with the microbiota in MS patients.
Collapse
Affiliation(s)
- Léo Boussamet
- Nantes Université, Inserm, CHU de Nantes, CR2TI (Center for Research On Transplantation and Translational Immunology), 30 Bd Jean Monnet, 44000, Nantes, France
| | - Emmanuel Montassier
- Nantes Université, Inserm, CHU de Nantes, CR2TI (Center for Research On Transplantation and Translational Immunology), 30 Bd Jean Monnet, 44000, Nantes, France
- Emergency Department, Nantes Hospital, Nantes, France
| | - Camille Mathé
- Nantes Université, Inserm, CHU de Nantes, CR2TI (Center for Research On Transplantation and Translational Immunology), 30 Bd Jean Monnet, 44000, Nantes, France
| | - Alexandra Garcia
- Nantes Université, Inserm, CHU de Nantes, CR2TI (Center for Research On Transplantation and Translational Immunology), 30 Bd Jean Monnet, 44000, Nantes, France
| | - Jérémy Morille
- Nantes Université, Inserm, CHU de Nantes, CR2TI (Center for Research On Transplantation and Translational Immunology), 30 Bd Jean Monnet, 44000, Nantes, France
| | - Sita Shah
- Nantes Université, Inserm, CHU de Nantes, CR2TI (Center for Research On Transplantation and Translational Immunology), 30 Bd Jean Monnet, 44000, Nantes, France
| | - Emilie Dugast
- Nantes Université, Inserm, CHU de Nantes, CR2TI (Center for Research On Transplantation and Translational Immunology), 30 Bd Jean Monnet, 44000, Nantes, France
| | - Sandrine Wiertlewski
- Nantes Université, Inserm, CHU de Nantes, CR2TI (Center for Research On Transplantation and Translational Immunology), 30 Bd Jean Monnet, 44000, Nantes, France
- Neurology Department, Nantes Hospital, Nantes, France
| | | | - Corinna Bang
- Institute of Clinical Molecular Biology, Christian Albrechts University of Kiel, Kiel, Germany
| | - Klarissa H Stürner
- Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - Damien Masson
- Clinical Biochemistry Department, Nantes Hospital, Nantes, France
| | - Arnaud B Nicot
- Nantes Université, Inserm, CHU de Nantes, CR2TI (Center for Research On Transplantation and Translational Immunology), 30 Bd Jean Monnet, 44000, Nantes, France
| | - Nicolas Vince
- Nantes Université, Inserm, CHU de Nantes, CR2TI (Center for Research On Transplantation and Translational Immunology), 30 Bd Jean Monnet, 44000, Nantes, France
| | - David-Axel Laplaud
- Nantes Université, Inserm, CHU de Nantes, CR2TI (Center for Research On Transplantation and Translational Immunology), 30 Bd Jean Monnet, 44000, Nantes, France
- Neurology Department, Nantes Hospital, Nantes, France
| | - Douglas L Feinstein
- Jesse Brown VA Medical Center, 835 South Wolcott Ave, MC513, E720, Chicago, IL, 60612, USA.
- Department of Anesthesiology, University of Illinois, Chicago, IL, USA.
| | - Laureline Berthelot
- Nantes Université, Inserm, CHU de Nantes, CR2TI (Center for Research On Transplantation and Translational Immunology), 30 Bd Jean Monnet, 44000, Nantes, France.
| |
Collapse
|
3
|
Salin A, Dugast E, Lardeux V, Solinas M, Belujon P. The amygdala-ventral pallidum pathway contributes to a hypodopaminergic state in the ventral tegmental area during protracted abstinence from chronic cocaine. Br J Pharmacol 2023; 180:1819-1831. [PMID: 36645812 DOI: 10.1111/bph.16034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Revised: 12/01/2022] [Accepted: 01/06/2023] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND AND PURPOSE Incubation of craving, the progressive increase in drug seeking over the first weeks of abstinence, is associated with temporal changes during abstinence in the activity of several structures involved in drug-seeking behaviour. Decreases of dopamine (DA) release and DA neuronal activity (hypodopaminergic state) have been reported in the ventral tegmental area (VTA) during cocaine abstinence, but the mechanisms underlying these neuroadaptations are not well understood. We investigated the potential involvement of a VTA inhibiting circuit (basolateral amygdala [BLA]-ventral pallidum [VP] pathway) in the hypodopaminergic state associated with abstinence from chronic cocaine. EXPERIMENTAL APPROACH In a model of cocaine self-administration, we performed in vivo electrophysiological recordings of DA VTA neurons and BLA neurons from anaesthetised rats during early and protracted abstinence and evaluated the involvement of the BLA-VP pathway using a pharmacological approach. KEY RESULTS We found significant decreases in VTA DA population activity and significant increases in BLA activity after protracted but not after short-term abstinence from chronic cocaine. The decrease in VTA DA activity was restored by pharmacological inhibition of the activity of either the BLA or the VP, suggesting that these regions exert a negative influence on DA activity. CONCLUSION AND IMPLICATIONS Our study sheds new lights on neuroadaptations occurring during incubation of craving leading to relapse. In particular, we describe the involvement of the BLA-VP pathway in cocaine-induced decreases of DA activity in the VTA. This study adds important information about the specific brain network dysfunctions underlying hypodopaminergic activity during abstinence.
Collapse
Affiliation(s)
- Adélie Salin
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
- Université de Rennes, Institut Numecan INRAE, INSERM, Rennes, France
| | - Emilie Dugast
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
- CHU de Poitiers, Poitiers, France
| | - Virginie Lardeux
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
| | - Marcello Solinas
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
| | - Pauline Belujon
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
| |
Collapse
|
4
|
Garcia A, Dugast E, Shah S, Morille J, Lebrun-Frenay C, Thouvenot E, De Sèze J, Le Page E, Vukusic S, Maurousset A, Berger E, Casez O, Labauge P, Ruet A, Raposo C, Bakdache F, Buffels R, Le Frère F, Nicot A, Wiertlewski S, Gourraud PA, Berthelot L, Laplaud D. Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm 2023; 10:10/3/e200091. [PMID: 36810163 PMCID: PMC9944617 DOI: 10.1212/nxi.0000000000200091] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Accepted: 12/12/2022] [Indexed: 02/23/2023]
Abstract
BACKGROUND AND OBJECTIVES Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS). We assessed early cellular immune profiles and their association with disease activity at treatment start and under therapy, which may provide new clues on the mechanisms of action of OCR and on the disease pathophysiology. METHODS A first group of 42 patients with an early RR-MS, never exposed to disease-modifying therapy, was included in 11 centers participating to an ancillary study of the ENSEMBLE trial (NCT03085810) to evaluate the effectiveness and safety of OCR. The phenotypic immune profile was comprehensively assessed by multiparametric spectral flow cytometry at baseline and after 24 and 48 weeks of OCR treatment on cryopreserved peripheral blood mononuclear cells and analyzed in relation to disease clinical activity. A second group of 13 untreated patients with RR-MS was included for comparative analysis of peripheral blood and CSF. The transcriptomic profile was assessed by single-cell qPCRs of 96 genes of immunologic interest. RESULTS Using an unbiased analysis, we found that OCR as an effect on 4 clusters of CD4+ T cells: one corresponding to naive CD4+ T cells was increased, the other clusters corresponded to effector memory (EM) CD4+CCR6- T cells expressing homing and migration markers, 2 of them also expressing CCR5 and were decreased by the treatment. Of interest, one CD8+ T-cell cluster was decreased by OCR corresponding to EM CCR5-expressing T cells with high expression of the brain homing markers CD49d and CD11a and correlated with the time elapsed since the last relapse. These EM CD8+CCR5+ T cells were enriched in the CSF of patients with RR-MS and corresponded to activated and cytotoxic cells. DISCUSSION Our study provides novel insights into the mode of action of anti-CD20, pointing toward the role of EM T cells, particularly a subset of CD8 T cells expressing CCR5.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - David Laplaud
- From the CHU Nantes (A.G., E.D., S.S., J.M., A.N., S.W., P.-A.G., L.B., D.L.), Nantes Université, INSERM UMR1064, Center for Research in Transplantation and Translational Immunology (CR2TI); CRCSEP (C.L.-F.), CHU de Nice Pasteur 2, Université Nice Côte d'Azur UR2CA URRIS; Service de Neurologie (E.T.), CHU de Nîmes, Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM; Service de Neurologie et Centre d'Investigation Clinique (J.D.S.), CHU de Strasbourg; Service de Neurologie (E.L.P.), CHU Pontchaillou, Rennes; Université de Lyon (S.V.), Université Claude Bernard Lyon 1; Service de Neurologie (S.V.), sclérose en plaques, pathologies de la Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron; Observatoire Français de la Sclérose en Plaques (S.V.), Centre de Recherche en Neurosciences de Lyon; EUGENE DEVIC EDMUS Foundation Against Multiple sclerosis (S.V.), state-approved Foundation, Bron; Service de Neurologie (A.M.), CHU Bretonneau, Tours; Service de Neurologie (E.B.), CHU de Besançon; Service de Neurologie (O.C.), CHU de Grenoble; Service de Neurologie (P.L.), CHU de Montpellier, Montpellier; Service de Neurologie (A.R.), CHU de Bordeaux; Université de Bordeaux (A.R.), INSERM, Neurocentre Magendie; F. Hoffmann-La Roche Ltd (C.R., F.B., R.B.) CIC INSERM 1413 (F.L.F., S.W., D.L.), Nantes; CHU Nantes (S.W., D.L.), Nantes Université, Service de Neurologie; and CHU Nantes (P.-A.G.), Nantes Université, Clinique des données, France.
| |
Collapse
|
5
|
Nicot AB, Harb J, Garcia A, Guillot F, Mai HL, Mathé CV, Morille J, Vallino A, Dugast E, Shah SP, Lefrère F, Moyon M, Wiertlewski S, Le Berre L, Renaudin K, Soulillou JP, van Pesch V, Brouard S, Berthelot L, Laplaud DA. Aglycosylated extracellular loop of inwardly rectifying potassium channel 4.1 (KCNJ10) provides a target for autoimmune neuroinflammation. Brain Commun 2023; 5:fcad044. [PMID: 36910419 PMCID: PMC9994600 DOI: 10.1093/braincomms/fcad044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 09/20/2022] [Accepted: 02/21/2023] [Indexed: 02/25/2023] Open
Abstract
Multiple sclerosis is an autoimmune disease of the central nervous system. Yet, the autoimmune targets are still undefined. The extracellular e1 sequence of KCNJ10, the inwardly rectifying potassium channel 4.1, has been subject to fierce debate for its role as a candidate autoantigen in multiple sclerosis. Inwardly rectifying potassium channel 4.1 is expressed in the central nervous system but also in peripheral tissues, raising concerns about the central nervous system-specificity of such autoreactivity. Immunization of C57Bl6/J female mice with the e1 peptide (amino acids 83-120 of Kir4.1) induced anti-e1 immunoglobulin G- and T-cell responses and promoted demyelinating encephalomyelitis with B cell central nervous system enrichment in leptomeninges and T cells/macrophages in central nervous system parenchyma from forebrain to spinal cord, mostly in the white matter. Within our cohort of multiple sclerosis patients (n = 252), 6% exhibited high anti-e1 immunoglobulin G levels in serum as compared to 0.7% in the control cohort (n = 127; P = 0.015). Immunolabelling of inwardly rectifying potassium channel 4.1-expressing white matter glia with the anti-e1 serum from immunized mice increased during murine autoimmune neuroinflammation and in multiple sclerosis white matter as compared with controls. Strikingly, the mouse and human anti-e1 sera labelled astrocytoma cells when N-glycosylation was blocked with tunicamycin. Western blot confirmed that neuroinflammation induces Kir4.1 expression, including its shorter aglycosylated form in murine experimental autoencephalomyelitis and multiple sclerosis. In addition, recognition of inwardly rectifying potassium channel 4.1 using mouse anti-e1 serum in Western blot experiments under unreduced conditions or in cells transfected with the N-glycosylation defective N104Q mutant as compared to the wild type further suggests that autoantibodies target an e1 conformational epitope in its aglycosylated form. These data highlight the e1 sequence of inwardly rectifying potassium channel 4.1 as a valid central nervous system autoantigen with a disease/tissue-specific post-translational antigen modification as potential contributor to autoimmunity in some multiple sclerosis patients.
Collapse
Affiliation(s)
- Arnaud B Nicot
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Jean Harb
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Alexandra Garcia
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Flora Guillot
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Hoa-Le Mai
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Camille V Mathé
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Jérémy Morille
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Amélie Vallino
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Emilie Dugast
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Sita P Shah
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Fabienne Lefrère
- Service de Neurologie, CHU Nantes, Nantes 44000, France.,CIC Inserm 1413, CHU Nantes, Nantes 44000, France
| | - Mélinda Moyon
- Service de Neurologie, CHU Nantes, Nantes 44000, France.,CIC Inserm 1413, CHU Nantes, Nantes 44000, France
| | - Sandrine Wiertlewski
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France.,Service de Neurologie, CHU Nantes, Nantes 44000, France.,CIC Inserm 1413, CHU Nantes, Nantes 44000, France
| | - Ludmilla Le Berre
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Karine Renaudin
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Jean-Paul Soulillou
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Vincent van Pesch
- Neurologie, Institute of Neuroscience, Université Catholique de Louvain, Bruxelles 1200, Belgium
| | - Sophie Brouard
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - Laureline Berthelot
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France
| | - David-Axel Laplaud
- INSERM, Nantes Université, CHU Nantes, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, Nantes 44000, France.,Service de Neurologie, CHU Nantes, Nantes 44000, France.,CIC Inserm 1413, CHU Nantes, Nantes 44000, France
| |
Collapse
|
6
|
Nicolas C, Hofford RS, Dugast E, Lardeux V, Belujon P, Solinas M, Bardo MT, Thiriet N. Prevention of relapse to methamphetamine self-administration by environmental enrichment: involvement of glucocorticoid receptors. Psychopharmacology (Berl) 2022; 239:1009-1018. [PMID: 33768375 DOI: 10.1007/s00213-021-05770-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2020] [Accepted: 01/21/2021] [Indexed: 12/17/2022]
Abstract
RATIONALE In rodents, environmental enrichment (EE) produces both preventive and curative effects on drug addiction, and this effect is believed to depend at least in part on EE's actions on the stress system. OBJECTIVES This study investigated whether exposure to EE during abstinence reduces methamphetamine seeking after extended self-administration. In addition, we investigated whether these effects are associated with alterations in the levels of glucocorticoid receptors (GR) in the brain and whether administration of GR antagonists blocks methamphetamine relapse. METHODS We allowed rats to self-administer methamphetamine for twenty 14-h sessions. After 3 weeks of abstinence either in standard (SE) or EE conditions, we measured methamphetamine seeking in a single 3-h session. Then, we used western blot techniques to measure GR levels in several brain areas. Finally, in an independent group of rats, after methamphetamine self-administration and abstinence in SE, we administered the GR antagonist mifepristone, and we investigated methamphetamine seeking. RESULTS Exposure to EE reduced methamphetamine seeking and reversed methamphetamine-induced increases in GR levels in the ventral and dorsal hippocampus. In addition, EE decreased GR levels in the amygdala in drug-naive animals, but this effect was prevented by previous exposure to methamphetamine. Administration of mifepristone significantly decreased methamphetamine seeking. CONCLUSIONS The anti-craving effects of EE are paralleled by restoration of methamphetamine-induced dysregulation of GR in the hippocampus. These results provide support for the hypothesis that the effect of EE on methamphetamine relapse is at least in part mediated by EE's action on the brain stress system.
Collapse
Affiliation(s)
- Céline Nicolas
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
| | - Rebecca S Hofford
- Department of Psychology, University of Kentucky, Lexington, KY, 40536-0509, USA
| | - Emilie Dugast
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France.,CHU de Poitiers, Poitiers, France
| | - Virginie Lardeux
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
| | - Pauline Belujon
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
| | - Marcello Solinas
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France
| | - Michael T Bardo
- Department of Psychology, University of Kentucky, Lexington, KY, 40536-0509, USA
| | - Nathalie Thiriet
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France.
| |
Collapse
|
7
|
Vallino A, Dos Santos A, Mathé CV, Garcia A, Morille J, Dugast E, Shah SP, Héry-Arnaud G, Guilloux CA, Gleeson PJ, Monteiro RC, Soulillou JP, Harb J, Bigot-Corbel E, Michel L, Wiertlewski S, Nicot AB, Laplaud DA, Berthelot L. Gut bacteria Akkermansia elicit a specific IgG response in CSF of patients with MS. Neurol Neuroimmunol Neuroinflamm 2020; 7:7/3/e688. [PMID: 32123045 PMCID: PMC7136044 DOI: 10.1212/nxi.0000000000000688] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/25/2019] [Accepted: 01/17/2020] [Indexed: 11/15/2022]
Affiliation(s)
- Amélie Vallino
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Amélie Dos Santos
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Camille V Mathé
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Alexandra Garcia
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Jérémy Morille
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Emilie Dugast
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Sita P Shah
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Geneviève Héry-Arnaud
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Charles-Antoine Guilloux
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Patrick J Gleeson
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Renato C Monteiro
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Jean-Paul Soulillou
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Jean Harb
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Edith Bigot-Corbel
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Laure Michel
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Sandrine Wiertlewski
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Arnaud B Nicot
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - David-Axel Laplaud
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France
| | - Laureline Berthelot
- From the Centre de Recherche en Transplantation et Immunologie UMR1064 (A.V., A.D.S., C.V.M., A.G., J.M., E.D., S.P.S., J.-P.S., J.H., L.M., S.W., A.B.N., D.A.L., L.B.), INSERM, Université de Nantes; Univ Brest (G.H.-A., C.-A.G.), Inserm, EFS, UMR 1078, GGB; Unité de Bactériologie (G.H.-A.), Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, Brest; Centre de Recherche sur l'Inflammation UMRS1149 (P.J.G., R.C.M.), INSERM, Université Paris Diderot, CNRS ERL8252; Department of biochemistry (J.H., E.B.-C.), CHU Nantes; Department of Neurology (L.M., S.W., D.-A.L.), CHU Nantes; and CIC 1214 (A.G., L.M., S.W., D.-A.L.), CHU Nantes, France.
| |
Collapse
|
8
|
Barba T, Harb J, Koenig A, Mathias V, Rabeyrin M, Dugast E, Morelon E, Brouard S, Dubois V, Thaunat O. Le niveau de sialylation des anticorps spécifiques du donneur est variable mais n’impacte pas la sévérité du rejet humoral. Nephrol Ther 2019. [DOI: 10.1016/j.nephro.2019.07.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Barba T, Harb J, Ducreux S, Koenig A, Mathias V, Rabeyrin M, Pouliquen E, Sicard A, Chartoire D, Dugast E, Defrance T, Morelon E, Brouard S, Dubois V, Thaunat O. Highly Variable Sialylation Status of Donor-Specific Antibodies Does Not Impact Humoral Rejection Outcomes. Front Immunol 2019; 10:513. [PMID: 30949173 PMCID: PMC6435580 DOI: 10.3389/fimmu.2019.00513] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Accepted: 02/26/2019] [Indexed: 12/19/2022] Open
Abstract
Clinical outcome in antibody-mediated rejection (AMR) shows high inter-individual heterogeneity. Sialylation status of the Fc fragment of IgGs is variable, which could modulate their ability to bind to C1q and/or Fc receptors. In this translational study, we evaluated whether DSA sialylation influence AMR outcomes. Among 938 kidney transplant recipients for whom a graft biopsy was performed between 2004 and 2012 at Lyon University Hospitals, 69 fulfilled the diagnosis criteria for AMR and were enrolled. Sera banked at the time of the biopsy were screened for the presence of DSA by Luminex. The sialylation status of total IgG and DSA was quantified using Sambucus nigra agglutinin-based chromatography. All patients had similar levels of sialylation of serum IgGs (~2%). In contrast, the proportion of sialylated DSA were highly variable (median = 9%; range = 0–100%), allowing to distribute the patients in two groups: high DSA sialylation (n = 44; 64%) and low DSA sialylation (n = 25; 36%). The two groups differed neither on the intensity of rejection lesions (C4d, ptc, and g; p > 0.05) nor on graft survival rates (Log rank test, p = 0.99). in vitro models confirmed the lack of impact of Fc sialylation on the ability of a monoclonal antibody to trigger classical complement cascade and activate NK cells. We conclude that DSA sialylation status is highly variable but has not impact on DSA pathogenicity and AMR outcome.
Collapse
Affiliation(s)
- Thomas Barba
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France
| | - Jean Harb
- French National Institute of Health and Medical Research (INSERM) UMR1064, Nantes, France.,Laboratory of Biochemistry, Nantes University Hospital, Nantes, France
| | | | - Alice Koenig
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.,Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France
| | - Virginie Mathias
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,French National Blood Service (EFS), HLA Laboratory, Lyon, France
| | - Maud Rabeyrin
- Department of Pathology, Hospices Civils de Lyon, Bron, France
| | - Eric Pouliquen
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.,Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France
| | - Antoine Sicard
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.,Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France
| | - Dimitri Chartoire
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France
| | - Emilie Dugast
- French National Institute of Health and Medical Research (INSERM) UMR1064, Nantes, France
| | - Thierry Defrance
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France
| | - Emmanuel Morelon
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.,Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France
| | - Sophie Brouard
- French National Institute of Health and Medical Research (INSERM) UMR1064, Nantes, France
| | - Valérie Dubois
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,French National Blood Service (EFS), HLA Laboratory, Lyon, France
| | - Olivier Thaunat
- French National Institute of Health and Medical Research (INSERM) Unit 1111, Lyon, France.,Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.,Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France
| |
Collapse
|
10
|
Alsebaaly J, Dugast E, Favot L, Rabbaa Khabbaz L, Solinas M, Thiriet N. Persistent Neuroadaptations in the Expression of Genes Involved in Cholesterol Homeostasis Induced by Chronic, Voluntary Alcohol Intake in Rats. Front Mol Neurosci 2018; 11:457. [PMID: 30618609 PMCID: PMC6300585 DOI: 10.3389/fnmol.2018.00457] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2018] [Accepted: 11/27/2018] [Indexed: 12/29/2022] Open
Abstract
Alcohol use disorder (AUD) is associated with persistent adaptations in the brain that are believed to participate in the long-lasting vulnerability to relapse after abstinence. Cholesterol, the major sterol compound found in the central nervous system (CNS), plays a major role in maintenance of neuronal morphology, synaptogenesis and synaptic communication and may be involved in alcohol-induced neuroadaptations. In this study, we investigated whether alcohol consumption in a two-bottle choice paradigm followed by 3 weeks of abstinence could alter the expression of genes encoding proteins involved in cholesterol homeostasis in brain regions involved in addiction and relapse, namely the prefrontal cortex (PFC), the nucleus accumbens (NAc), the mesencephalon and the amygdala. We found that voluntary alcohol intake followed by 3 weeks of forced abstinence produces changes in the transcription of several genes encoding proteins directly involved in cholesterol synthesis such as 3-hydroxyl-3-methylglutaryl-coenzyme A (HMGCoA) reductase, farnesyl-diphosphate farnesyltransferase 1 (FDFT1) and farnesyl diphosphate synthase (FDPS) and in its regulation such as sterol regulatory element-binding factor-2 (SREBF2), in cholesterol transport such as ATP-binding cassette subfamily A member 1 (ABCA1) and in cholesterol degradation such as CYP46A1. Interestingly, these changes appeared to be region-specific and suggest that previous chronic exposure to alcohol might durably increase cholesterol metabolism in the PFC, the NAc and the mesencephalon and decrease cholesterol metabolism in the amygdala. Altogether, these results suggest that alcohol consumption leads to durable deregulations in cholesterol metabolism in key areas involved in loss of control over drug use and addiction. These long-term neuroadaptations may participate in the changes in brain structure and functioning that are responsible for the long-lasting risks of relapse to alcohol.
Collapse
Affiliation(s)
- Josette Alsebaaly
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM, U-1084, Poitiers, France
- Laboratoire de Pharmacologie, Pharmacie Clinique et Contrôle de Qualité des Médicaments (LPCQM), Faculty of Pharmacy, PTS, University of Saint-Joseph of Beirut, Beirut, Lebanon
| | - Emilie Dugast
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM, U-1084, Poitiers, France
- CHU de Poitiers, Poitiers, France
| | - Laure Favot
- Laboratoire Inflammation, Tissus Epithéliaux et Cytokines (LITEC), EA4331, University of Poitiers, Poitiers, France
| | - Lydia Rabbaa Khabbaz
- Laboratoire de Pharmacologie, Pharmacie Clinique et Contrôle de Qualité des Médicaments (LPCQM), Faculty of Pharmacy, PTS, University of Saint-Joseph of Beirut, Beirut, Lebanon
| | - Marcello Solinas
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM, U-1084, Poitiers, France
| | - Nathalie Thiriet
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM, U-1084, Poitiers, France
| |
Collapse
|
11
|
Michel G, Blery P, Henoux M, Guicheux J, Weiss P, Dugast E, Brouard S, Malard O, Espitalier F. Correction: Bone marrow cell extract promotes the regeneration of irradiated bone. PLoS One 2018; 13:e0196145. [PMID: 29664946 PMCID: PMC5903616 DOI: 10.1371/journal.pone.0196145] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0178060.].
Collapse
|
12
|
Dugast E, David G, Oger R, Danger R, Judor JP, Gagne K, Chesneau M, Degauque N, Soulillou JP, Paul P, Picard C, Guerif P, Conchon S, Giral M, Gervois N, Retière C, Brouard S. Corrigendum: Broad Impairment of Natural Killer Cells From Operationally Tolerant Kidney Transplanted Patients. Front Immunol 2018; 9:589. [PMID: 29617012 PMCID: PMC5879121 DOI: 10.3389/fimmu.2018.00589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Accepted: 03/08/2018] [Indexed: 11/23/2022] Open
Affiliation(s)
- Emilie Dugast
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Gaëlle David
- Etablissement Français du sang, Nantes, France.,CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Romain Oger
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Richard Danger
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Jean-Paul Judor
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Katia Gagne
- Etablissement Français du sang, Nantes, France.,CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,LabEx Transplantex, Université de Strasbourg, France
| | - Mélanie Chesneau
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Nicolas Degauque
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Jean-Paul Soulillou
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Pascale Paul
- Nephrology Dialysis Renal Transplantation Center, Assistance Publique des Hôpitaux de Marseille, Hospital de la Conception, UMR 1076, Vascular Research Center of Marseille, INSERM, Aix-Marseille University, Marseille, France
| | - Christophe Picard
- Établissement Français du Sang Alpes Méditerranée, Marseille, France.,ADES UMR 7268, CNRS, EFS, Aix-Marseille Université, Marseille, France
| | - Pierrick Guerif
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.,CIC Biotherapy, CHU Nantes, Nantes, France
| | - Sophie Conchon
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Magali Giral
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.,CIC Biotherapy, CHU Nantes, Nantes, France
| | - Nadine Gervois
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Christelle Retière
- Etablissement Français du sang, Nantes, France.,CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Sophie Brouard
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| |
Collapse
|
13
|
Ingrand I, Solinas M, Ingrand P, Dugast E, Saulnier PJ, Pérault-Pochat MC, Lafay-Chebassier C. Lack of effects of simvastatin on smoking cessation in humans: A double-blind, randomized, placebo-controlled clinical study. Sci Rep 2018; 8:3836. [PMID: 29497063 PMCID: PMC5832803 DOI: 10.1038/s41598-018-21819-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Accepted: 01/29/2018] [Indexed: 11/17/2022] Open
Abstract
A recent pre-clinical study has shown that brain-penetrating statins can reduce risks of relapse to cocaine and nicotine addiction in rats. Based on this information, we conducted a randomized, double-blind, placebo-controlled, proof-of-concept trial to assess the efficacy of simvastatin in smoking cessation. After informed consent, 118 participants received behavioral cessation support and were randomly assigned to a 3-month treatment with simvastatin or placebo. The primary outcome was biochemically verified abstinence or smoking reduction at 3-month post-target quit date (TQD). Secondary outcomes were abstinence during weeks 9-12 post-TQD, prolonged abstinence or reduction at months 6 and 12 post-TQD, safety and craving assessed at each visit during the 3-month period of treatment. Simvastatin treatment was not associated with higher 3-month abstinence or smoking reduction compared to placebo. There was no significant difference in any of the secondary outcomes. Simvastatin was well tolerated. Over 3 and 9 months follow-up period, 78% simvastatin and 69% placebo participants were retained in the study. At 6 and 12 months, smoking remained significantly reduced from baseline in both groups. Our results demonstrate that a 3-month simvastatin treatment (40 mg/day), added to individual behavioral cessation support, does not improve significantly smoking cessation compared to placebo in humans.
Collapse
Affiliation(s)
- Isabelle Ingrand
- INSERM, Clinical Investigation Center CIC 1402, University of Poitiers, CHU Poitiers, Poitiers, France
- Department of Epidemiology & Biostatistics, Faculty of Medicine, Poitiers, France
| | - Marcello Solinas
- INSERM U-1084, Experimental and Clinical Neurosciences Laboratory, University of Poitiers, Poitiers, France
| | - Pierre Ingrand
- INSERM, Clinical Investigation Center CIC 1402, University of Poitiers, CHU Poitiers, Poitiers, France
- Department of Epidemiology & Biostatistics, Faculty of Medicine, Poitiers, France
| | - Emilie Dugast
- INSERM, Clinical Investigation Center CIC 1402, University of Poitiers, CHU Poitiers, Poitiers, France
- INSERM U-1084, Experimental and Clinical Neurosciences Laboratory, University of Poitiers, Poitiers, France
| | - Pierre-Jean Saulnier
- INSERM, Clinical Investigation Center CIC 1402, University of Poitiers, CHU Poitiers, Poitiers, France
| | - Marie-Christine Pérault-Pochat
- INSERM, Clinical Investigation Center CIC 1402, University of Poitiers, CHU Poitiers, Poitiers, France
- INSERM U-1084, Experimental and Clinical Neurosciences Laboratory, University of Poitiers, Poitiers, France
- Department of Clinical Pharmacology, Poitiers University Hospital, Poitiers, France
| | - Claire Lafay-Chebassier
- INSERM, Clinical Investigation Center CIC 1402, University of Poitiers, CHU Poitiers, Poitiers, France.
- INSERM U-1084, Experimental and Clinical Neurosciences Laboratory, University of Poitiers, Poitiers, France.
- Department of Clinical Pharmacology, Poitiers University Hospital, Poitiers, France.
| |
Collapse
|
14
|
Dugast E, David G, Oger R, Danger R, Judor JP, Gagne K, Chesneau M, Degauque N, Soulillou JP, Paul P, Picard C, Guerif P, Conchon S, Giral M, Gervois N, Retière C, Brouard S. Broad Impairment of Natural Killer Cells from Operationally Tolerant Kidney Transplanted Patients. Front Immunol 2017; 8:1721. [PMID: 29312288 PMCID: PMC5732263 DOI: 10.3389/fimmu.2017.01721] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Accepted: 11/21/2017] [Indexed: 01/10/2023] Open
Abstract
The role of natural killer (NK) cells in organ transplantation is controversial. This study aims to decipher their role in kidney transplant tolerance in humans. Previous studies highlighted several modulated genes involved in NK cell biology in blood from spontaneously operationally tolerant patients (TOLs; drug-free kidney-transplanted recipients with stable graft function). We performed a phenotypic, functional, and genetic characterization of NK cells from these patients compared to kidney-transplanted patients with stable graft function under immunosuppression and healthy volunteers (HVs). Both operationally TOLs and stable patients harbored defective expression of the NKp46 activator receptor and lytic molecules perforin and granzyme compared to HVs. Surprisingly, NK cells from operationally TOLs also displayed decreased expression of the CD16 activating marker (in the CD56Dim NK cell subset). This decrease was associated with impairment of their functional capacities upon stimulation, as shown by lower interferon gamma (IFNγ) production and CD107a membranous expression in a reverse antibody-dependent cellular cytotoxicity (ADCC) assay, spontaneous lysis assays, and lower target cell lysis in the 51Cr release assay compared to HVs. Conversely, despite impaired K562 cell lysis in the 51Cr release assay, patients with stable graft function harbored a normal reverse ADCC and even increased amounts of IFNγ+ NK cells in the spontaneous lysis assay. Altogether, the strong impairment of the phenotype and functional cytotoxic capacities of NK cells in operationally TOLs may accord with the establishment of a pro-tolerogenic environment, despite remaining highly activated after transplantation in patients with stable graft function.
Collapse
Affiliation(s)
- Emilie Dugast
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Gaëlle David
- Etablissement Français du sang, Nantes, France.,CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Romain Oger
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Richard Danger
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Jean-Paul Judor
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Katia Gagne
- Etablissement Français du sang, Nantes, France.,CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,LabEx Transplantex, Université de Strasbourg, France
| | - Mélanie Chesneau
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Nicolas Degauque
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | | | - Pascale Paul
- Nephrology Dialysis Renal Transplantation Center, Assistance Publique des Hôpitaux de Marseille, Hospital de la Conception, UMR 1076, Vascular Research Center of Marseille, INSERM, Aix-Marseille University, Marseille, France
| | - Christophe Picard
- Établissement Français du Sang Alpes Méditerranée, Marseille, France.,ADES UMR 7268, CNRS, EFS, Aix-Marseille Université, Marseille, France
| | - Pierrick Guerif
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.,CIC Biotherapy, CHU Nantes, Nantes, France
| | - Sophie Conchon
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Magali Giral
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.,CIC Biotherapy, CHU Nantes, Nantes, France
| | - Nadine Gervois
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Christelle Retière
- Etablissement Français du sang, Nantes, France.,CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Sophie Brouard
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| |
Collapse
|
15
|
Nicol B, Salou M, Vogel I, Garcia A, Dugast E, Morille J, Kilens S, Charpentier E, Donnart A, Nedellec S, Jacq-Foucher M, Le Frère F, Wiertlewski S, Bourreille A, Brouard S, Michel L, David L, Gourraud PA, Degauque N, Nicot AB, Berthelot L, Laplaud DA. An intermediate level of CD161 expression defines a novel activated, inflammatory, and pathogenic subset of CD8 + T cells involved in multiple sclerosis. J Autoimmun 2017; 88:61-74. [PMID: 29054368 DOI: 10.1016/j.jaut.2017.10.005] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2017] [Revised: 10/05/2017] [Accepted: 10/08/2017] [Indexed: 11/18/2022]
Abstract
Several lines of evidence support a key role for CD8+ T cells in central nervous system tissue damage of patients with multiple sclerosis. However, the precise phenotype of the circulating CD8+ T cells that may be recruited from the peripheral blood to invade the CNS remains largely undefined to date. It has been suggested that IL-17 secreting CD8 (Tc17) T cells may be involved, and in humans these cells are characterized by the expression of CD161. We focused our study on a unique and recently described subset of CD8 T cells characterized by an intermediate expression of CD161 as its role in neuroinflammation has not been investigated to date. The frequency, phenotype, and function of CD8+ T cells with an intermediate CD161 expression level were characterized ex-vivo, in vitro, and in situ using RNAseq, RT-PCR, flow cytometry, TCR sequencing, and immunohistofluorescence of cells derived from healthy volunteers (n = 61), MS subjects (n = 90), as well as inflammatory (n = 15) and non-inflammatory controls (n = 6). We report here that CD8+CD161int T cells present characteristics of effector cells, up-regulate cell-adhesion molecules and have an increased ability to cross the blood-brain barrier and to secrete IL-17, IFNγ, GM-CSF, and IL-22. We further demonstrate that these cells are recruited and enriched in the CNS of MS subjects where they produce IL-17. In the peripheral blood, RNAseq, RT-PCR, high-throughput TCR repertoire analyses, and flow cytometry confirmed an increased effector and transmigration pattern of these cells in MS patients, with the presence of supernumerary clones compared to healthy controls. Our data demonstrate that intermediate levels of CD161 expression identifies activated and effector CD8+ T cells with pathogenic properties that are recruited to MS lesions. This suggests that CD161 may represent a biomarker and a valid target for the treatment of neuroinflammation.
Collapse
Affiliation(s)
- Bryan Nicol
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France
| | - Marion Salou
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France
| | - Isabel Vogel
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Alexandra Garcia
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Emilie Dugast
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Jeremy Morille
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Stéphanie Kilens
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France
| | - Eric Charpentier
- INSERM UMR1087, CNRS UMR6291, Université de Nantes, l'institut du thorax, Nantes, F-44000, France
| | - Audrey Donnart
- INSERM UMR1087, CNRS UMR6291, Université de Nantes, l'institut du thorax, Nantes, F-44000, France
| | - Steven Nedellec
- SFR François Bonamy, Cellular and Tissue Imaging Core Facility (MicroPICell), Nantes, France
| | | | | | - Sandrine Wiertlewski
- SFR François Bonamy, Cellular and Tissue Imaging Core Facility (MicroPICell), Nantes, France; Service de Neurologie, CHU Nantes, Nantes, France
| | - Arnaud Bourreille
- INSERM 015, Centre d'Investigation Clinique, Nantes, France; Institut des Maladies de l'Appareil Digestif, CIC-04 Inserm, CHU Nantes, Nantes, France
| | - Sophie Brouard
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Laure Michel
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; Service de Neurologie, CHU Nantes, Nantes, France
| | - Laurent David
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; INSERM UMS 016, SFR Francois Bonamy, iPSC Core Facility, Nantes, France; UMR CNRS 3556, Nantes, F-44000, France; Université de Nantes, Nantes, F-44000, France; CHU de Nantes, Nantes, F-44000, France; LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Pierre-Antoine Gourraud
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France
| | - Nicolas Degauque
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Arnaud B Nicot
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Laureline Berthelot
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - David-Axel Laplaud
- Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; Service de Neurologie, CHU Nantes, Nantes, France; INSERM 015, Centre d'Investigation Clinique, Nantes, France.
| |
Collapse
|
16
|
Chenouard A, Chesneau M, Bui Nguyen L, Le Bot S, Cadoux M, Dugast E, Paul C, Malard-Castagnet S, Ville S, Guérif P, Soulillou JP, Degauque N, Danger R, Giral M, Brouard S. Renal Operational Tolerance Is Associated With a Defect of Blood Tfh Cells That Exhibit Impaired B Cell Help. Am J Transplant 2017; 17:1490-1501. [PMID: 27888555 DOI: 10.1111/ajt.14142] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Revised: 11/20/2016] [Accepted: 11/22/2016] [Indexed: 01/25/2023]
Abstract
Renal operationally tolerant patients (TOL) display a defect in B cell differentiation, with a deficiency in plasma cells. Recently described, T follicular helper (Tfh) cells play a critical role in B cell differentiation. We analyzed blood Tfh subsets in TOL and transplanted patients with stable graft function under immunosuppression (STA). We observed a reduced proportion of blood activated and highly functional Tfh subsets in TOL, without affecting Tfh absolute numbers. Functionally, Tfh cells from TOL displayed a modified gene expression profile, failed to produce interleukin-21, and were unable to induce IgG production by naive B cells. This Tfh defect is linked to a low incidence of postgraft de novo donor-specific antibody (dnDSA) immunization, suggesting that the lack of Tfh cells in TOL may induce a protolerogenic environment with reduced risk of developing dnDSA. Finally, we showed that elevated Tfh in STA precedes the occurrence of dnDSA during an alloresponse. These data provide new insights into the mechanisms of antibody response in operational tolerance. Disrupted homeostasis and impaired Tfh function in TOL could lead to a reduced risk of developing dnDSA and suggest a predictive role of blood Tfh cells on the occurrence of dnDSA in transplant recipients.
Collapse
Affiliation(s)
- A Chenouard
- INSERM, Nantes, France.,Faculté de Médecine, Université de Nantes, Nantes, France.,CHU de Nantes, ITUN, Nantes, France
| | - M Chesneau
- INSERM, Nantes, France.,Faculté de Médecine, Université de Nantes, Nantes, France
| | - L Bui Nguyen
- INSERM, Nantes, France.,Faculté de Médecine, Université de Nantes, Nantes, France
| | - S Le Bot
- INSERM, Nantes, France.,Faculté de Médecine, Université de Nantes, Nantes, France
| | - M Cadoux
- INSERM, Nantes, France.,CHU de Nantes, ITUN, Nantes, France
| | - E Dugast
- INSERM, Nantes, France.,Faculté de Médecine, Université de Nantes, Nantes, France
| | - C Paul
- INSERM, Nantes, France.,CHU de Nantes, ITUN, Nantes, France
| | - S Malard-Castagnet
- CHU de Nantes, ITUN, Nantes, France.,Laboratoire HLA, Etablissement Français du Sang Pays de la Loire, Nantes, France
| | - S Ville
- INSERM, Nantes, France.,Faculté de Médecine, Université de Nantes, Nantes, France.,CHU de Nantes, ITUN, Nantes, France
| | - P Guérif
- INSERM, Nantes, France.,CHU de Nantes, ITUN, Nantes, France.,CIC Biothérapie, Nantes, France
| | - J-P Soulillou
- LabEx Transplantex, Nantes, France.,EU Consortium BIO-DrIM
| | - N Degauque
- INSERM, Nantes, France.,CHU de Nantes, ITUN, Nantes, France.,EU Consortium VISICORT
| | - R Danger
- INSERM, Nantes, France.,Faculté de Médecine, Université de Nantes, Nantes, France
| | - M Giral
- INSERM, Nantes, France.,Faculté de Médecine, Université de Nantes, Nantes, France.,CHU de Nantes, ITUN, Nantes, France.,CIC Biothérapie, Nantes, France.,LabEx Transplantex, Nantes, France.,EU Consortium BIO-DrIM
| | - S Brouard
- INSERM, Nantes, France.,CHU de Nantes, ITUN, Nantes, France.,CIC Biothérapie, Nantes, France.,LabEx Transplantex, Nantes, France.,EU Consortium BIO-DrIM.,EU Consortium VISICORT.,Immunotherapy Graft Oncology, LabEx IGO, Nantes, France
| |
Collapse
|
17
|
Le Berre L, Rousse J, Gourraud PA, Imbert-Marcille BM, Salama A, Evanno G, Semana G, Nicot A, Dugast E, Guérif P, Adjaoud C, Freour T, Brouard S, Agbalika F, Marignier R, Brassat D, Laplaud DA, Drouet E, Van Pesch V, Soulillou JP. Decrease of blood anti-α1,3 Galactose Abs levels in multiple sclerosis (MS) and clinically isolated syndrome (CIS) patients. Clin Immunol 2017; 180:128-135. [PMID: 28506921 DOI: 10.1016/j.clim.2017.05.006] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Revised: 03/17/2017] [Accepted: 05/05/2017] [Indexed: 02/07/2023]
Abstract
The etiology of multiple sclerosis (MS) remains elusive. Among the possible causes, the increase of anti-Neu5Gc antibodies during EBV primo-infection of Infectious mononucleosis (IMN) may damage the integrity of the blood-brain barrier facilitating the transfer of EBV-infected B cells and anti-EBV T cell clones in the brain. We investigated the change in titers of anti-Neu5Gc and anti-α1,3 Galactose antibodies in 49 IMN, in 76 MS, and 73 clinically isolated syndrome (CIS) patients, as well as age/gender-matched healthy individuals. Anti-Gal and anti-Neu5Gc are significantly increased during IMN (p=0.02 and p<1.10-4 respectively), but not in acute CMV primo-infection. We show that, whereas there was no change in anti-Neu5Gc in MS/CIS, the two populations exhibit a significant decrease in anti-Gal (combined p=2.7.10-3), in contrast with patients with non-MS/CIS central nervous system pathologies. Since anti-Gal result from an immunization against α1,3 Gal, lacking in humans but produced in the gut, our data suggest that CIS and MS patients have an altered microbiota or an altered response to this microbiotic epitope.
Collapse
Affiliation(s)
- L Le Berre
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
| | - J Rousse
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France; Xenothera, Nantes, F44000 France
| | - P-A Gourraud
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - B-M Imbert-Marcille
- EA 4271 - Immunovirologie et Polymorphisme Génétique, Centre Hospitalo-Universitaire de Nantes, Nantes, F44093, France
| | - A Salama
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France; Xenothera, Nantes, F44000 France
| | - G Evanno
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France; Xenothera, Nantes, F44000 France
| | - G Semana
- INSERM, UMR 917 - University of Rennes, Rennes, F35016 France; EFS Bretagne Rennes, F35016 France
| | - A Nicot
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - E Dugast
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - P Guérif
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - C Adjaoud
- Centre Hospitalo-Universitaire de Nantes - Ecole Sages Femmes - Hopital Mere Enfant, Nantes, F44000 France
| | - T Freour
- Laboratoire de Biologie du Développement et de la Reproduction, CHU de Nantes, Nantes, F44093 France
| | - S Brouard
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - F Agbalika
- Unit of Virology, Saint-Louis Hospital AP-HP, Université Paris-Diderot, Paris VII F75010, France
| | - R Marignier
- INSERM UMR 1028 - Centre de Recherche en Neurosciences de Lyon, Faculté de médecine - RTH Laënnec, Lyon, F69372 France
| | - D Brassat
- Department of Neurology - CHU Toulouse, Toulouse, F31300 France
| | - D-A Laplaud
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - E Drouet
- Institute of Structural Biology, University Grenoble Alpes, UMR CNRS CEA UGA 5545 CEA, CNRS 38044 Grenoble, F38042 France
| | - V Van Pesch
- Unité de Neurochimie, Institute of Neuroscience, Université catholique de Louvain, Belgium
| | - J-P Soulillou
- Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| |
Collapse
|
18
|
Dugast E, Soulillou JP, Foucher Y, Papuchon E, Guerif P, Paul C, Riochet D, Chesneau M, Cesbron A, Renaudin K, Dantal J, Giral M, Brouard S. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. Am J Transplant 2016; 16:3255-3261. [PMID: 27367750 DOI: 10.1111/ajt.13946] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Revised: 06/10/2016] [Accepted: 06/22/2016] [Indexed: 01/25/2023]
Abstract
Long-term renal transplant outcome is limited by side effects of immunosuppressive drugs, particularly calcineurin inhibitor (CNI). We assumed that some patients selected for a "low immunological risk of rejection" could be eligible and benefit from a CNI weaning strategy. We designed a prospective, randomized, multicenter, double-blind placebo-controlled clinical study (Eudract: 2010-019574-33) to analyze the benefit-risk ratio of tacrolimus weaning on highly selected patients (≥4 years of transplantation, normal histology, stable graft function, no anti-HLA immunization). The primary endpoint was improvement of renal function. Fifty-two patients were scheduled in each treatment arm, placebo compared to the CNI maintenance arm. Only 10 patients were eligible and randomized. Five patients were assigned to the placebo arm and five were assigned to the tacrolimus maintenance arm. In the tacrolimus maintenance arm, all patients maintained stable graft function and no immunological events occurred. Contrastingly, in the placebo arm, all five patients had to reintroduce a full dose of tacrolimus since three of them presented an acute rejection episode (one humoral, one mixed, and one borderline) and two displayed anti-HLA antibodies without histological lesion (one donor-specific antibodies [DSA] and one non-DSA). Clearly, tacrolimus withdrawal must be avoided even in long-term highly selective stable kidney recipients.
Collapse
Affiliation(s)
- E Dugast
- ITUN, CHU de Nantes, INSERM, UMR 1064, Nantes, France.,Université de Nantes, Faculté de Médecine, Nantes, France
| | - J-P Soulillou
- ITUN, CHU de Nantes, INSERM, UMR 1064, Nantes, France.,Université de Nantes, Faculté de Médecine, Nantes, France
| | - Y Foucher
- Université de Nantes, SPHERE Laboratory EA4275, Nantes, France
| | - E Papuchon
- ITUN, CHU de Nantes, INSERM, UMR 1064, Nantes, France.,CIC Biothérapie, Nantes, France
| | - P Guerif
- ITUN, CHU de Nantes, INSERM, UMR 1064, Nantes, France.,CIC Biothérapie, Nantes, France
| | - C Paul
- ITUN, CHU de Nantes, INSERM, UMR 1064, Nantes, France
| | - D Riochet
- Department of Pediatrics, Nantes University Hospital, Nantes, France.,LUNAM University, INSERM, UMR 1064 ITUN, Nantes, France
| | - M Chesneau
- ITUN, CHU de Nantes, INSERM, UMR 1064, Nantes, France
| | - A Cesbron
- LabEx Transplantex, Nantes, France.,Etablissement Français du sang, Pays de la Loire, HLA Laboratory, Nantes, France
| | - K Renaudin
- ITUN, CHU de Nantes, INSERM, UMR 1064, Nantes, France.,Université de Nantes, Faculté de Médecine, Nantes, France
| | - J Dantal
- ITUN, CHU de Nantes, INSERM, UMR 1064, Nantes, France
| | - M Giral
- ITUN, CHU de Nantes, INSERM, UMR 1064, Nantes, France. .,Université de Nantes, Faculté de Médecine, Nantes, France. .,LabEx Transplantex, Nantes, France. .,EU consortium BIO-DrIM (www.biodrim.eu), Berlin, Germany.
| | - S Brouard
- ITUN, CHU de Nantes, INSERM, UMR 1064, Nantes, France.,LabEx Transplantex, Nantes, France.,EU consortium BIO-DrIM (www.biodrim.eu), Berlin, Germany.,LabEx IGO "Immunotherapy Graft Oncology", Nantes, France
| |
Collapse
|
19
|
Ducret E, Puaud M, Lacoste J, Belin-Rauscent A, Fouyssac M, Dugast E, Murray JE, Everitt BJ, Houeto JL, Belin D. N-acetylcysteine Facilitates Self-Imposed Abstinence After Escalation of Cocaine Intake. Biol Psychiatry 2016; 80:226-34. [PMID: 26592462 PMCID: PMC4954758 DOI: 10.1016/j.biopsych.2015.09.019] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Revised: 09/25/2015] [Accepted: 09/30/2015] [Indexed: 01/01/2023]
Abstract
BACKGROUND N-acetylcysteine (NAC) has been suggested to prevent relapse to cocaine seeking. However, the psychological processes underlying its potential therapeutic benefit remain largely unknown. METHODS We investigated the hallmark features of addiction that were influenced by chronic NAC treatment in rats given extended access to cocaine: escalation, motivation, self-imposed abstinence in the face of punishment, or propensity to relapse. For this, Sprague Dawley rats were given access either to 1 hour (short access) or 6 hours (long access [LgA]) self-administration (SA) sessions until LgA rats displayed a robust escalation. Rats then received daily saline or NAC (60 mg/kg, intraperitoneal) treatment and were tested under a progressive ratio and several consecutive sessions in which lever presses were punished by mild electric foot shocks. RESULTS NAC increased the sensitivity to punishment in LgA rats only, thereby promoting abstinence. Following the cessation of punishment, NAC-treated LgA rats failed to recover fully their prepunishment cocaine intake levels and resumed cocaine SA at a lower rate than short access and vehicle-treated LgA rats. However, NAC altered neither the escalation of SA nor the motivation for cocaine. At the neurobiological level, NAC reversed cocaine-induced decreases in the glutamate type 1 transporter observed in both the nucleus accumbens and the dorsolateral striatum. NAC also increased the expression of Zif268 in the nucleus accumbens and dorsolateral striatum of LgA rats. CONCLUSIONS Our results indicate that NAC contributes to the restoration of control over cocaine SA following adverse consequences, an effect associated with plasticity mechanisms in both the ventral and dorsolateral striatum.
Collapse
Affiliation(s)
- Eric Ducret
- French Institute of Health and Medical Research, Avenir Team Psychobiology of Compulsive Disorders, Université de Poitiers, Poitiers, France
| | - Mickaël Puaud
- Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom
| | - Jérôme Lacoste
- Service de Psychiatrie et Addictologie, Centre Hospitalier Universitaire de Fort-de-France, Martinique, France
| | - Aude Belin-Rauscent
- Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom
| | - Maxime Fouyssac
- Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom
| | - Emilie Dugast
- French Institute of Health and Medical Research, Avenir Team Psychobiology of Compulsive Disorders, Université de Poitiers, Poitiers, France
| | - Jennifer E Murray
- Department of Psychology, University of Cambridge, Cambridge, United Kingdom
| | - Barry J Everitt
- Department of Psychology, University of Cambridge, Cambridge, United Kingdom
| | - Jean-Luc Houeto
- Service de Neurologie de l'Hôpital de Poitiers and Center for Clinical Investigation-French Institute of Health and Medical Research, Poitiers, France
| | - David Belin
- Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom.
| |
Collapse
|
20
|
Malard-Castagnet S, Dugast E, Degauque N, Pallier A, Soulillou JP, Cesbron A, Giral M, Harb J, Brouard S. Sialylation of antibodies in kidney recipients with de novo donor specific antibody, with or without antibody mediated rejection. Hum Immunol 2015; 77:1076-1083. [PMID: 26546874 DOI: 10.1016/j.humimm.2015.10.021] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Revised: 10/06/2015] [Accepted: 10/08/2015] [Indexed: 10/22/2022]
Abstract
BACKGROUND DSA are associated with reduced long-term transplant function and increased prevalence of chronic rejection in some patients, whereas others do not: our goal was to determine whether the sialylation of IgG and DSA could help to explain in these last cases their "non-aggressive" and/or "protective" biological activity. METHODS The sialylation level of total IgG in blood from two groups of kidney-transplant patients with de novo DSA, one with an AMR (DSA+AMR+), and the other without were studied. RESULTS In the DSA+AMR- patients total IgG were more sialylated at time of transplant, and at the first detection of DSA, class I DSA were 2.6-fold more sialylated (mean 9.943±1.801 versus 3.898±2.475, p=0.058); DSA+AMR+ patients exhibited higher levels of class II DSA. CONCLUSIONS In our study, higher levels of sialylated IgG are detectable on day of transplant in patients who do not develop AMR, they have higher sialylated class I DSA at the initial detection of DSA, whereas class II DSA are significantly higher in patients who develop AMR. This is the first report suggesting that transplant outcome, and particularly AMR, is associated with levels of sialylated IgG antibodies. Our data suggest that DSA are functionally heterogeneous and that further studies with an enlarged cohort may improve our understanding of their clinical impact.
Collapse
Affiliation(s)
- Stéphanie Malard-Castagnet
- Etablissement Français du sang, Pays de la Loire, HLA Laboratory, 34 Boulevard Jean Monnet, 44011 Nantes, France; Institut National de la Sante Et de la Recherche Médicale INSERM U1064, and Institut de Transplantation Urologie Néphrologie du Centre Hospitalier Universitaire Hôtel Dieu, LabEx Transplantex, CHU de Nantes, 30 Boulevard Jean Monnet, 44093 Nantes Cedex 01, France.
| | - Emilie Dugast
- Institut National de la Sante Et de la Recherche Médicale INSERM U1064, and Institut de Transplantation Urologie Néphrologie du Centre Hospitalier Universitaire Hôtel Dieu, LabEx Transplantex, CHU de Nantes, 30 Boulevard Jean Monnet, 44093 Nantes Cedex 01, France; Université de Nantes, Faculté de Médecine, Nantes, France.
| | - Nicolas Degauque
- Institut National de la Sante Et de la Recherche Médicale INSERM U1064, and Institut de Transplantation Urologie Néphrologie du Centre Hospitalier Universitaire Hôtel Dieu, LabEx Transplantex, CHU de Nantes, 30 Boulevard Jean Monnet, 44093 Nantes Cedex 01, France; Université de Nantes, Faculté de Médecine, Nantes, France.
| | - Annaïck Pallier
- Institut National de la Sante Et de la Recherche Médicale INSERM U1064, and Institut de Transplantation Urologie Néphrologie du Centre Hospitalier Universitaire Hôtel Dieu, LabEx Transplantex, CHU de Nantes, 30 Boulevard Jean Monnet, 44093 Nantes Cedex 01, France.
| | - Jean Paul Soulillou
- Institut National de la Sante Et de la Recherche Médicale INSERM U1064, and Institut de Transplantation Urologie Néphrologie du Centre Hospitalier Universitaire Hôtel Dieu, LabEx Transplantex, CHU de Nantes, 30 Boulevard Jean Monnet, 44093 Nantes Cedex 01, France; Université de Nantes, Faculté de Médecine, Nantes, France.
| | - Anne Cesbron
- Etablissement Français du sang, Pays de la Loire, HLA Laboratory, 34 Boulevard Jean Monnet, 44011 Nantes, France.
| | - Magali Giral
- Institut National de la Sante Et de la Recherche Médicale INSERM U1064, and Institut de Transplantation Urologie Néphrologie du Centre Hospitalier Universitaire Hôtel Dieu, LabEx Transplantex, CHU de Nantes, 30 Boulevard Jean Monnet, 44093 Nantes Cedex 01, France; Université de Nantes, Faculté de Médecine, Nantes, France; CIC Biothérapie, 5, allée de l'Ile Gloriette, 44093 Nantes Cedex 0144035, Nantes, France; CHU Nantes, CRB, 9 quai Moncousu, 44093 Nantes Cedex 1, Nantes F-44093, France.
| | - Jean Harb
- Institut National de la Sante Et de la Recherche Médicale INSERM U1064, and Institut de Transplantation Urologie Néphrologie du Centre Hospitalier Universitaire Hôtel Dieu, LabEx Transplantex, CHU de Nantes, 30 Boulevard Jean Monnet, 44093 Nantes Cedex 01, France; Université de Nantes, Faculté de Médecine, Nantes, France.
| | - Sophie Brouard
- Institut National de la Sante Et de la Recherche Médicale INSERM U1064, and Institut de Transplantation Urologie Néphrologie du Centre Hospitalier Universitaire Hôtel Dieu, LabEx Transplantex, CHU de Nantes, 30 Boulevard Jean Monnet, 44093 Nantes Cedex 01, France; CIC Biothérapie, 5, allée de l'Ile Gloriette, 44093 Nantes Cedex 0144035, Nantes, France; CHU Nantes, CRB, 9 quai Moncousu, 44093 Nantes Cedex 1, Nantes F-44093, France.
| |
Collapse
|
21
|
Julian A, Dugast E, Ragot S, Krolak-Salmon P, Berrut G, Dantoine T, Hommet C, Hanon O, Page G, Paccalin M. There is no correlation between peripheral inflammation and cognitive status at diagnosis in Alzheimer's disease. Aging Clin Exp Res 2015; 27:589-94. [PMID: 25700558 DOI: 10.1007/s40520-015-0332-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2014] [Accepted: 02/10/2015] [Indexed: 12/18/2022]
Abstract
BACKGROUND Besides the neurofibrillary tangles and amyloid plaques, an inflammatory process is involved at central and peripheral levels in Alzheimer's disease (AD). We aimed to determine whether peripheral inflammatory parameter levels, in plasma and in peripheral blood mononuclear cells (PBMCs), could be correlated with the cognitive status at the time of AD diagnosis. METHODS Patients were included at diagnosis with MMSE score between 16 and 25 and were naive of symptomatic treatment for AD. C-reactive protein >10 mg/L and any acute or chronic inflammation were considered as exclusion criteria. Cognitive assessment also included the ADAScog scale. Plasma interleukins (IL)-1β, IL-6, tumor necrosis factor (TNF)-α and the chemokine ligand 5 (CCL5) were measured using Luminex(®) X-MAP(®) technology. A subgroup of patients also underwent measures of these parameters in extracellular and intracellular compartments of PBMCs (ancillary study). RESULTS One hundred and nine patients were included; mean age 79.4 ± 6.8 years with 37 patients in the ancillary study. The mean values of IL-1β, TNF-α, IL-6 and CCL5 values were 1.49, 7.18, 3.09 and 69,615.81 pg/mL, respectively. No correlation between plasma cytokines or chemokine levels and cognitive scores was found. In PBMCs, the levels of cytokines were detectable but did not either show any correlation with cognitive scores. CONCLUSION Our data indicate that at diagnosis, peripheral levels of cytokines and CCL5 display low values without any correlation with the cognitive status. Further results of our study will show if these circulating markers are related to the progression of AD.
Collapse
Affiliation(s)
- Adrien Julian
- Centre Mémoire de Ressources et de Recherche, Poitiers University Hospital, Poitiers, France.
- Department of Neurology, Poitiers University Hospital, Poitiers, France.
- EA3808 molecular Targets and Therapeutic of Alzheimer's disease, University of Poitiers, Pôle Biologie Santé Bâtiment B36/B37, Secteur β-Niveau 0, 1 Rue Georges Bonnet, TSA 51106, 86073, Poitiers Cedex 9, France.
| | - Emilie Dugast
- EA3808 molecular Targets and Therapeutic of Alzheimer's disease, University of Poitiers, Pôle Biologie Santé Bâtiment B36/B37, Secteur β-Niveau 0, 1 Rue Georges Bonnet, TSA 51106, 86073, Poitiers Cedex 9, France
- Centre d'Investigation Clinique, Poitiers University Hospital, Poitiers, France
| | - Stéphanie Ragot
- Centre d'Investigation Clinique, Poitiers University Hospital, Poitiers, France
| | - Pierre Krolak-Salmon
- Centre Mémoire de Ressources et de Recherche, Lyon University Hospital, Lyon, France
| | - Gilles Berrut
- Department of Geriatrics, Nantes University Hospital, Nantes, France
| | - Thierry Dantoine
- Department of Geriatrics, Limoges University Hospital, Limoges, France
| | - Caroline Hommet
- Centre Mémoire de Ressources et de Recherche, Tours University Hospital, Tours, France
| | - Olivier Hanon
- Department of Geriatrics, Paris Broca University Hospital, Paris, France
| | - Guylène Page
- EA3808 molecular Targets and Therapeutic of Alzheimer's disease, University of Poitiers, Pôle Biologie Santé Bâtiment B36/B37, Secteur β-Niveau 0, 1 Rue Georges Bonnet, TSA 51106, 86073, Poitiers Cedex 9, France
| | - Marc Paccalin
- Centre Mémoire de Ressources et de Recherche, Poitiers University Hospital, Poitiers, France
- EA3808 molecular Targets and Therapeutic of Alzheimer's disease, University of Poitiers, Pôle Biologie Santé Bâtiment B36/B37, Secteur β-Niveau 0, 1 Rue Georges Bonnet, TSA 51106, 86073, Poitiers Cedex 9, France
- Centre d'Investigation Clinique, Poitiers University Hospital, Poitiers, France
- Department of Geriatrics, Poitiers University Hospital, Poitiers, France
| |
Collapse
|
22
|
François A, Julian A, Ragot S, Dugast E, Blanchard L, Brishoual S, Chassaing D, Page G, Paccalin M. Inflammatory Stress on Autophagy in Peripheral Blood Mononuclear Cells from Patients with Alzheimer's Disease during 24 Months of Follow-Up. PLoS One 2015; 10:e0138326. [PMID: 26393801 PMCID: PMC4578953 DOI: 10.1371/journal.pone.0138326] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Accepted: 08/28/2015] [Indexed: 12/13/2022] Open
Abstract
Recent findings indicate that microglia in Alzheimer's disease (AD) is senescent whereas peripheral blood mononuclear cells (PBMCs) could infiltrate the brain to phagocyte amyloid deposits. However, the molecular mechanisms involved in the amyloid peptide clearance remain unknown. Autophagy is a physiological degradation of proteins and organelles and can be controlled by pro-inflammatory cytokines. The purpose of this study was to evaluate the impact of inflammation on autophagy in PBMCs from AD patients at baseline, 12 and 24 months of follow-up. Furthermore, PBMCs from healthy patients were also included and treated with 20 μM amyloid peptide 1-42 to mimic AD environment. For each patient, PBMCs were stimulated with the mitogenic factor, phytohaemagglutin (PHA), and treated with either 1 μM C16 as an anti-inflammatory drug or its vehicle. Autophagic markers (Beclin-1, p62/sequestosome 1 and microtubule-associated protein-light chain 3: LC3) were quantified by western blot and cytokines (Interleukin (IL)-1β, Tumor necrosis Factor (TNF)-α and IL-6) by Luminex X-MAP® technology. Beclin-1 and TNF-α levels were inversely correlated in AD PBMCs at 12 months post-inclusion. In addition, Beclin-1 and p62 increased in the low inflammatory environment induced by C16. Only LC3-I levels were inversely correlated with cognitive decline at baseline. For the first time, this study describes longitudinal changes in autophagic markers in PBMCs of AD patients under an inflammatory environment. Inflammation would induce autophagy in the PBMCs of AD patients while an anti-inflammatory environment could inhibit their autophagic response. However, this positive response could be altered in a highly aggressive environment.
Collapse
Affiliation(s)
- Arnaud François
- EA3808 Molecular Targets and Therapeutics of Alzheimer’s Disease, University of Poitiers, Poitiers, France
- * E-mail:
| | - Adrien Julian
- EA3808 Molecular Targets and Therapeutics of Alzheimer’s Disease, University of Poitiers, Poitiers, France
- Neurology Department, Poitiers University Hospital, Poitiers, France
- Centre Mémoire de Ressources et de Recherche, Poitiers University Hospital, Poitiers, France
- Geriatrics Department, Poitiers University Hospital, Poitiers, France
| | | | - Emilie Dugast
- EA3808 Molecular Targets and Therapeutics of Alzheimer’s Disease, University of Poitiers, Poitiers, France
- CIC-P 1402, Poitiers University Hospital, Poitiers, France
| | - Ludovic Blanchard
- Geriatrics Department, Poitiers University Hospital, Poitiers, France
- CIC-P 1402, Poitiers University Hospital, Poitiers, France
| | | | - Damien Chassaing
- EA3808 Molecular Targets and Therapeutics of Alzheimer’s Disease, University of Poitiers, Poitiers, France
| | - Guylène Page
- EA3808 Molecular Targets and Therapeutics of Alzheimer’s Disease, University of Poitiers, Poitiers, France
| | - Marc Paccalin
- EA3808 Molecular Targets and Therapeutics of Alzheimer’s Disease, University of Poitiers, Poitiers, France
- Centre Mémoire de Ressources et de Recherche, Poitiers University Hospital, Poitiers, France
- Geriatrics Department, Poitiers University Hospital, Poitiers, France
- CIC-P 1402, Poitiers University Hospital, Poitiers, France
| |
Collapse
|
23
|
Chesneau M, Michel L, Dugast E, Chenouard A, Baron D, Pallier A, Durand J, Braza F, Guerif P, Laplaud DA, Soulillou JP, Giral M, Degauque N, Chiffoleau E, Brouard S. Tolerant Kidney Transplant Patients Produce B Cells with Regulatory Properties. J Am Soc Nephrol 2015; 26:2588-98. [PMID: 25644114 DOI: 10.1681/asn.2014040404] [Citation(s) in RCA: 109] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2014] [Accepted: 12/11/2014] [Indexed: 12/14/2022] Open
Abstract
Whereas a B cell-transcriptional profile has been recorded for operationally tolerant kidney graft patients, the role that B cells have in this tolerance has not been reported. In this study, we analyzed the role of B cells from operationally tolerant patients, healthy volunteers, and kidney transplant recipients with stable graft function on T cell suppression. Proliferation, apoptosis, and type I proinflammatory cytokine production by effector CD4(+)CD25(-) T cells were measured after anti-CD3/anti-CD28 stimulation with or without autologous B cells. We report that B cells inhibit CD4(+)CD25(-) effector T cell response in a dose-dependent manner. This effect required B cells to interact with T-cell targets and was achieved through a granzyme B (GzmB)-dependent pathway. Tolerant recipients harbored a higher number of B cells expressing GzmB and displaying a plasma cell phenotype. Finally, GzmB(+) B-cell number was dependent on IL-21 production, and B cells from tolerant recipients but not from other patients positively regulated both the number of IL-21(+) T cells and IL-21 production, suggesting a feedback loop in tolerant recipients that increases excessive B cell activation and allows regulation to take place. These data provide insights into the characterization of B cell-mediated immunoregulation in clinical tolerance and show a potential regulatory effect of B cells on effector T cells in blood from patients with operationally tolerant kidney grafts.
Collapse
Affiliation(s)
- Mélanie Chesneau
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Faculty of Medicine, Nantes University, Nantes, France; and
| | - Laure Michel
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Faculty of Medicine, Nantes University, Nantes, France; and Institute of Transplantation Urology and Nephrology, Nantes University Hospital, Nantes, France
| | - Emilie Dugast
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Institute of Transplantation Urology and Nephrology, Nantes University Hospital, Nantes, France
| | - Alexis Chenouard
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Faculty of Medicine, Nantes University, Nantes, France; and
| | - Daniel Baron
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Faculty of Medicine, Nantes University, Nantes, France; and
| | - Annaïck Pallier
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France
| | - Justine Durand
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Faculty of Medicine, Nantes University, Nantes, France; and
| | - Faouzi Braza
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Faculty of Medicine, Nantes University, Nantes, France; and
| | - Pierrick Guerif
- Institute of Transplantation Urology and Nephrology, Nantes University Hospital, Nantes, France
| | - David-Axel Laplaud
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Faculty of Medicine, Nantes University, Nantes, France; and Institute of Transplantation Urology and Nephrology, Nantes University Hospital, Nantes, France
| | - Jean-Paul Soulillou
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Faculty of Medicine, Nantes University, Nantes, France; and Institute of Transplantation Urology and Nephrology, Nantes University Hospital, Nantes, France
| | - Magali Giral
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Faculty of Medicine, Nantes University, Nantes, France; and Institute of Transplantation Urology and Nephrology, Nantes University Hospital, Nantes, France
| | - Nicolas Degauque
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Faculty of Medicine, Nantes University, Nantes, France; and
| | - Elise Chiffoleau
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Faculty of Medicine, Nantes University, Nantes, France; and
| | - Sophie Brouard
- Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France; Faculty of Medicine, Nantes University, Nantes, France; and Institute of Transplantation Urology and Nephrology, Nantes University Hospital, Nantes, France
| |
Collapse
|
24
|
Braza F, Dugast E, Panov I, Paul C, Vogt K, Pallier A, Chesneau M, Baron D, Guerif P, Lei H, Laplaud DA, Volk HD, Degauque N, Giral M, Soulillou JP, Sawitzki B, Brouard S. Central Role of CD45RA- Foxp3hi Memory Regulatory T Cells in Clinical Kidney Transplantation Tolerance. J Am Soc Nephrol 2015; 26:1795-805. [PMID: 25556168 DOI: 10.1681/asn.2014050480] [Citation(s) in RCA: 92] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Accepted: 10/19/2014] [Indexed: 12/21/2022] Open
Abstract
The role of Foxp3(+) regulatory T cells (Tregs) in operational tolerance remains elusive, as initial results revealed an increased frequency of this subset in tolerant patients but no functional differences compared with immunosuppressed recipients. In addition, recent studies of regulatory B cells strongly suggest that Tregs may not have a central role in kidney transplantation tolerance. However, recent investigations of the crucial role of Foxp3 demethylation in Treg function and the possibility of identifying distinct Foxp3 T cell subsets prompted us to more thoroughly characterize Tregs in operationally tolerant patients. Thus, we studied the level of demethylation of the Foxp3 Treg-specific demethylated region (TSDR) in circulating CD4(+) T cells and analyzed Treg subset frequency in tolerant patients, healthy volunteers, patients with stable graft function under immunosuppression, and chronically rejecting recipients. We observed a higher proportion of CD4(+) T cells with demethylated Foxp3 and a specific expansion of CD4(+) CD45RA(-) Foxp3(hi) memory Tregs exclusively in tolerant patients. The memory Tregs of tolerant recipients exhibited increased Foxp3 TSDR demethylation, expressed higher levels of CD39 and glucocorticoid-induced TNF-related receptor, and harbored greater suppressive properties than memory Tregs from patients with stable graft function. Taken together, our data demonstrate that operationally tolerant patients mobilize an array of potentially suppressive cells, including not only regulatory B cells but also Tregs. Our results also indicate that tolerant patients have potent CD4(+)CD45RA(-) Foxp3(hi) memory Tregs with a specific Foxp3 TSDR demethylation pattern, which may contribute to the maintenance of graft tolerance.
Collapse
Affiliation(s)
- Faouzi Braza
- Faculty of Medicine, University of Nantes, Nantes, France; French Institute of Health and Medical Research Unit 1064, Research Institute on Urology, Nephrology, and Transplantation, and
| | - Emilie Dugast
- French Institute of Health and Medical Research Unit 1064, Research Institute on Urology, Nephrology, and Transplantation, and Biotherapy Clinical Investigation Center, Hôtel Dieu University Hospital, Nantes, France; and
| | - Ivo Panov
- Institute of Medical Immunology and Berlin Brandenburg Center for Regenerative Therapies, Charité Medical University, Berlin, Germany
| | - Chloé Paul
- French Institute of Health and Medical Research Unit 1064, Research Institute on Urology, Nephrology, and Transplantation, and Biotherapy Clinical Investigation Center, Hôtel Dieu University Hospital, Nantes, France; and
| | | | - Annaick Pallier
- French Institute of Health and Medical Research Unit 1064, Research Institute on Urology, Nephrology, and Transplantation, and Biotherapy Clinical Investigation Center, Hôtel Dieu University Hospital, Nantes, France; and
| | - Mélanie Chesneau
- Faculty of Medicine, University of Nantes, Nantes, France; French Institute of Health and Medical Research Unit 1064, Research Institute on Urology, Nephrology, and Transplantation, and
| | - Daniel Baron
- Faculty of Medicine, University of Nantes, Nantes, France; French Institute of Health and Medical Research Unit 1064, Research Institute on Urology, Nephrology, and Transplantation, and
| | - Pierrick Guerif
- Biotherapy Clinical Investigation Center, Hôtel Dieu University Hospital, Nantes, France; and
| | - Hong Lei
- Institute of Medical Immunology and Berlin Brandenburg Center for Regenerative Therapies, Charité Medical University, Berlin, Germany
| | - David-Axel Laplaud
- French Institute of Health and Medical Research Unit 1064, Research Institute on Urology, Nephrology, and Transplantation, and Biotherapy Clinical Investigation Center, Hôtel Dieu University Hospital, Nantes, France; and
| | - Hans-Dieter Volk
- Institute of Medical Immunology and Berlin Brandenburg Center for Regenerative Therapies, Charité Medical University, Berlin, Germany
| | - Nicolas Degauque
- French Institute of Health and Medical Research Unit 1064, Research Institute on Urology, Nephrology, and Transplantation, and Biotherapy Clinical Investigation Center, Hôtel Dieu University Hospital, Nantes, France; and
| | - Magali Giral
- French Institute of Health and Medical Research Unit 1064, Research Institute on Urology, Nephrology, and Transplantation, and Biotherapy Clinical Investigation Center, Hôtel Dieu University Hospital, Nantes, France; and
| | - Jean-Paul Soulillou
- French Institute of Health and Medical Research Unit 1064, Research Institute on Urology, Nephrology, and Transplantation, and Biotherapy Clinical Investigation Center, Hôtel Dieu University Hospital, Nantes, France; and
| | - Birgit Sawitzki
- Institute of Medical Immunology and Berlin Brandenburg Center for Regenerative Therapies, Charité Medical University, Berlin, Germany
| | - Sophie Brouard
- French Institute of Health and Medical Research Unit 1064, Research Institute on Urology, Nephrology, and Transplantation, and Biotherapy Clinical Investigation Center, Hôtel Dieu University Hospital, Nantes, France; and
| |
Collapse
|
25
|
Ansquer S, Belin-Rauscent A, Dugast E, Duran T, Benatru I, Mar AC, Houeto JL, Belin D. Atomoxetine decreases vulnerability to develop compulsivity in high impulsive rats. Biol Psychiatry 2014; 75:825-32. [PMID: 24252357 DOI: 10.1016/j.biopsych.2013.09.031] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Revised: 09/19/2013] [Accepted: 09/21/2013] [Indexed: 11/30/2022]
Abstract
BACKGROUND The factors contributing to the development and severity of obsessive-compulsive spectrum disorders such as obsessive-compulsive disorder, Tourette's syndrome, pathological gambling, and addictions remain poorly understood, limiting the development of therapeutic and preventive strategies. Recent evidence indicates that impulse-control deficits may contribute to the severity of compulsivity in several of these disorders. This suggests that impulsivity may be a transnosological endophenotype of vulnerability to compulsivity. However, the precise nature of the link between impulsivity and compulsivity in anxiety-related compulsive disorders remains unknown. METHODS We investigated the relationship between impulsivity and the development of a compulsive behavior in rats, which captures the hallmarks of compulsivity as defined in the DSM-IV--namely, that it is maladaptive, excessive, repetitive, and anxiolytic. RESULTS We demonstrate that a high-impulsivity trait, as measured in the five-choice serial reaction time task, predicts an increased propensity to develop compulsivity as measured in a schedule-induced polydipsia procedure. Trait impulsivity and compulsivity were nonlinearly related. This impulsivity-compulsivity relationship was lost after the development of compulsivity or under chronic treatment with atomoxetine, a noradrenergic reuptake inhibitor used to treat attention-deficit/hyperactivity disorder. Atomoxetine treatment both decreased impulsivity and prevented the development of compulsivity in high-impulsive animals. CONCLUSIONS These observations provide insight into the reciprocal influence of impulsivity and compulsivity in compulsive disorders and suggest that atomoxetine may be a useful treatment for patients suffering from obsessive-compulsive spectrum disorders with high impulsivity.
Collapse
Affiliation(s)
- Solène Ansquer
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1084-LNEC Experimental and Clinical Neurosciences Laboratory, Poitiers, France; Team Psychobiology of Compulsive Disorders, University of Poitiers, Poitiers, France; Service de Neurologie de l'Hôpital de Poitiers, Poitiers, France
| | - Aude Belin-Rauscent
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1084-LNEC Experimental and Clinical Neurosciences Laboratory, Poitiers, France; Team Psychobiology of Compulsive Disorders, University of Poitiers, Poitiers, France; INSERM European Associated Laboratory Psychobiology of Compulsive Habits, Cambridge, United Kingdom; INSERM CIC-0802, Poitiers, France
| | - Emilie Dugast
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1084-LNEC Experimental and Clinical Neurosciences Laboratory, Poitiers, France; Team Psychobiology of Compulsive Disorders, University of Poitiers, Poitiers, France; INSERM European Associated Laboratory Psychobiology of Compulsive Habits, Cambridge, United Kingdom
| | - Théo Duran
- Department of Psychology, Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, United Kingdom; Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom
| | - Isabelle Benatru
- Service de Neurologie de l'Hôpital de Poitiers, Poitiers, France; CNRS GDR 3557 "Institut de Psychiatrie", Poitiers, France
| | - Adam C Mar
- Hôpital Sainte Anne, Paris, France; Institut des Neurosciences de Grenoble-CR Inserm U.836; Université Joseph Fourier-Site Santé La Tronche-CHU Grenoble, Grenoble, France
| | - Jean-Luc Houeto
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1084-LNEC Experimental and Clinical Neurosciences Laboratory, Poitiers, France; Team Psychobiology of Compulsive Disorders, University of Poitiers, Poitiers, France; INSERM European Associated Laboratory Psychobiology of Compulsive Habits, Cambridge, United Kingdom; CNRS GDR 3557 "Institut de Psychiatrie", Poitiers, France
| | - David Belin
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1084-LNEC Experimental and Clinical Neurosciences Laboratory, Poitiers, France; Team Psychobiology of Compulsive Disorders, University of Poitiers, Poitiers, France; INSERM European Associated Laboratory Psychobiology of Compulsive Habits, Cambridge, United Kingdom; INSERM CIC-0802, Poitiers, France.
| |
Collapse
|
26
|
Dugast E, Chesneau M, Soulillou JP, Brouard S. Biomarkers and possible mechanisms of operational tolerance in kidney transplant patients. Immunol Rev 2014; 258:208-17. [DOI: 10.1111/imr.12156] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Emilie Dugast
- INSERM UMR 1064; Nantes France
- Centaure; Nantes France
| | - Mélanie Chesneau
- INSERM UMR 1064; Nantes France
- Université de Nantes; Nantes France
| | - Jean-Paul Soulillou
- INSERM UMR 1064; Nantes France
- Centaure; Nantes France
- CHU de Nantes; Nantes France
- Université de Nantes; Nantes France
| | - Sophie Brouard
- INSERM UMR 1064; Nantes France
- Centaure; Nantes France
- CHU de Nantes; Nantes France
- Université de Nantes; Nantes France
| |
Collapse
|
27
|
Degauque N, Ngono AE, Akl A, Lepetit M, Crochette R, Giral M, Lepourry J, Pallier A, Castagnet S, Dugast E, Guillot-Gueguen C, Jacq-Foucher M, Saulquin X, Cesbron A, Laplaud D, Nicot A, Brouard S, Soulillou JP. Characterization of antigen-specific B cells using nominal antigen-coated flow-beads. PLoS One 2013; 8:e84273. [PMID: 24386360 PMCID: PMC3875494 DOI: 10.1371/journal.pone.0084273] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Accepted: 11/13/2013] [Indexed: 12/12/2022] Open
Abstract
In order to characterize the reactivity of B cells against nominal antigens, a method based on the coupling of antigens onto the surface of fluorescent core polystyrene beads was developed. We first demonstrate that murine B cells with a human MOG-specific BCR are able to interact with MOG-coated beads and do not recognize beads coated with human albumin or pp65. B cells purified from human healthy volunteer blood or immunized individuals were tested for their ability to interact with various nominal antigens, including viral, vaccine, self and alloantigens, chosen for their usefulness in studying a variety of pathological processes. A substantial amount of B cells binding self-antigen MOG-coated beads can be detected in normal blood. Furthermore, greater frequencies of B cell against anti-Tetanic Toxin or anti-EBNA1 were observed in primed individuals. This method can reveal increased frequencies of anti-HLA committed B cells in patients with circulating anti-HLA antibodies compared to unsensitized patients and normal individuals. Of interest, those specific CD19 cells were preferentially identified within CD27(-)IgD(+) (i-e naïve) subset. These observations suggest that a broad range of medical situations could benefit from a tool that allows the detection, the quantification and the characterization of antigen-specific blood B cells.
Collapse
Affiliation(s)
- Nicolas Degauque
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Annie Elong Ngono
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Ahmed Akl
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Maud Lepetit
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Romain Crochette
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Magali Giral
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Julie Lepourry
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Annaick Pallier
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Stéphanie Castagnet
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Emilie Dugast
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | | | | | - Xavier Saulquin
- Université de Nantes, Faculté de Médecine, Nantes, France
- INSERM, UMR892, Nantes, France
| | - Anne Cesbron
- Etablissement Français du Sang, Laboratoire HLA, Nantes, France
| | - David Laplaud
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
- INSERM, CIC 004, Nantes, France
| | - Arnaud Nicot
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Sophie Brouard
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Jean-Paul Soulillou
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
- * E-mail:
| |
Collapse
|
28
|
Dugast E, Kiss-Toth E, Docherty L, Danger R, Chesneau M, Pichard V, Judor JP, Pettré S, Conchon S, Soulillou JP, Brouard S, Ashton-Chess J. Identification of tribbles-1 as a novel binding partner of Foxp3 in regulatory T cells. J Biol Chem 2013; 288:10051-10060. [PMID: 23417677 DOI: 10.1074/jbc.m112.448654] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
In a previous study, we identified TRIB1, a serine-threonine kinase-like molecule, as a biomarker of chronic antibody-mediated rejection of human kidneys when measured in peripheral blood mononuclear cells. Here, we focused our analysis on a specific subset of peripheral blood mononuclear cells that play a dominant role in regulating immune responses in health and disease, so-called CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs). We isolated both human and murine Treg and non-Treg counterparts and analyzed TRIB1 and Foxp3 mRNA expression by quantitative PCR on the freshly isolated cells or following 24 h of activation. Physical interaction between the human TRIB1 and Foxp3 proteins was analyzed in live cell lines by protein complementation assay using both flow cytometry and microscopy and confirmed in primary freshly isolated human CD4(+)CD25(hi)CD127(-) Tregs by co-immunoprecipitation. Both TRIB1 and Foxp3 were expressed at significantly higher levels in Tregs than in their CD4(+)CD25(-) counterparts (p < 0.001). Moreover, TRIB1 and Foxp3 mRNA levels correlated tightly in Tregs (Spearman r = 1.0; p < 0.001, n = 7), but not in CD4(+)CD25(-) T cells. The protein complementation assay revealed a direct physical interaction between TRIB1 and Foxp3 in live cells. This interaction was impaired upon deletion of the TRIB1 N-terminal but not the C-terminal domain, suggesting an interaction in the nucleus. This direct interaction within the nucleus was confirmed in primary human Tregs by co-immunoprecipitation. These data show a direct relationship between TRIB1 and Foxp3 in terms of their expression and physical interaction and highlight Tribbles-1 as a novel binding partner of Foxp3 in Tregs.
Collapse
Affiliation(s)
- Emilie Dugast
- UMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; TcLand Expression, 21 rue de la Noue Bras de Fer, 44200 Nantes, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France
| | - Endre Kiss-Toth
- Department of Cardiovascular Science, University of Sheffield, Sheffield S10 2TN, United Kingdom
| | - Louise Docherty
- Department of Cardiovascular Science, University of Sheffield, Sheffield S10 2TN, United Kingdom
| | - Richard Danger
- UMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France
| | - Mélanie Chesneau
- UMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France
| | - Virginie Pichard
- UMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France
| | - Jean-Paul Judor
- UMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France
| | - Ségolène Pettré
- UMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France
| | - Sophie Conchon
- UMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Faculté de Médecine Université de Nantes, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France
| | - Jean-Paul Soulillou
- UMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France; Centre Hospitalier Universitaire de Nantes, Nantes 44000, France
| | - Sophie Brouard
- UMR1064, Institut National de la Santé et de la Recherche Médicale, Nantes 44000, France; Institut de Recherche en Transplantation, Institut de Transplantation Urologie-Néphrologie, Nantes 44000, France; Centre Hospitalier Universitaire de Nantes, Nantes 44000, France.
| | | |
Collapse
|
29
|
Dugast E, Kiss-Toth E, Soulillou JP, Brouard S, Ashton-Chess J. The Tribbles-1 Protein in Humans: Roles and Functions in Health and Disease. Curr Mol Med 2013. [DOI: 10.2174/156652413804486197] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
30
|
Dugast E, Kiss-Toth E, Soulillou JP, Brouard S, Ashton-Chess J. The Tribbles-1 protein in humans: roles and functions in health and disease. Curr Mol Med 2013; 13:80-85. [PMID: 22834837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2012] [Revised: 06/05/2012] [Accepted: 06/08/2012] [Indexed: 06/01/2023]
Abstract
This review describes the key role of the serine-threonine kinase like protein Tribbles-1 in health as well as in diverse human pathologies. Tribbles-1 is a homolog protein of the Drosophila Tribbles. In Drosophila, the Tribbles protein is involved in the cell-cycle progression during mitosis and in mammals initial data showed TRIB1 to be involved in cell proliferation. In mammals, TRIB1 lacks a catalytic domain and thus acts as an adaptor protein by interacting with several partners. The activity of TRIB1 seems to be very specific to the environment and the cells type in which it is expressed, and a role for this molecule has been mainly described in several pathological states including various cancers such as acute myeloid leukemia and ovarian cancer. Further evidence has also linked TRIB1 to the control of plasmalipid homeostasis thus indicating the role of this molecule as a risk factor for myocardial infarction. Finally, TRIB1 is shown to be up-regulated during inflammatory events such as chronic inflammation of atherosclerotic arteries or chronic antibody-mediated rejection of transplanted organs. Here we provide a review of the current state of the scientific literature for TRIB1, highlighting its role in diverse pathologies and inflammatory states. A better understanding of the role of this protein as both a target as well as a biological marker in diseases should drive the development of new therapeutic strategies.
Collapse
Affiliation(s)
- E Dugast
- UMR643, INSERM, Nantes 44000, France
| | | | | | | | | |
Collapse
|
31
|
Dugast E, Kiss-Toth E, Soulillou JP, Brouard S, Ashton-Chess J. The Tribbles-1 Protein in Humans: Roles and Functions in Health and Disease. Curr Mol Med 2012. [DOI: 10.2174/1566524011307010080] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
32
|
Julian A, Dugast E, Dantoine T, Krolak-Salmon P, Berrut G, Hommet C, Hanon O, Beauchet O, Blanc F, Ornon C, Bouyer C, Blanchard L, Ragot S, Page G, Paccalin M. Correlation between peripheral inflammatory cytokines and cognitive performance at the time of diagnosis in Alzheimer's disease: Preliminary reports concerning the cohort cytocogma. Eur Geriatr Med 2012. [DOI: 10.1016/j.eurger.2012.07.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Racapé M, Duong Van Huyen JP, Danger R, Giral M, Bleicher F, Foucher Y, Pallier A, Pilet P, Tafelmeyer P, Ashton-Chess J, Dugast E, Pettré S, Charreau B, Soulillou JP, Brouard S. The involvement of SMILE/TMTC3 in endoplasmic reticulum stress response. PLoS One 2011; 6:e19321. [PMID: 21603654 PMCID: PMC3095597 DOI: 10.1371/journal.pone.0019321] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2010] [Accepted: 03/31/2011] [Indexed: 01/08/2023] Open
Abstract
Background Thestate of operational tolerance has been detected sporadically in some renal transplanted patients that stopped immunosuppressive drugs, demonstrating that allograft tolerance might exist in humans. Several years ago, a study by Brouard et al. identified a molecular signature of several genes that were significantly differentially expressed in the blood of such patients compared with patients with other clinical situations. The aim of the present study is to analyze the role of one of these molecules over-expressed in the blood of operationally tolerant patients, SMILE or TMTC3, a protein whose function is still unknown. Methodology/Principal Findings We first confirmed that SMILE mRNA is differentially expressed in the blood of operationally tolerant patients with drug-free long term graft function compared to stable and rejecting patients. Using a yeast two-hybrid approach and a colocalization study by confocal microscopy we furthermore report an interaction of SMILE with PDIA3, a molecule resident in the endoplasmic reticulum (ER). In accordance with this observation, SMILE silencing in HeLa cells correlated with the modulation of several transcripts involved in proteolysis and a decrease in proteasome activity. Finally, SMILE silencing increased HeLa cell sensitivity to the proteasome inhibitor Bortezomib, a drug that induces ER stress via protein overload, and increased transcript expression of a stress response protein, XBP-1, in HeLa cells and keratinocytes. Conclusion/Significance In this study we showed that SMILE is involved in the endoplasmic reticulum stress response, by modulating proteasome activity and XBP-1 transcript expression. This function of SMILE may influence immune cell behavior in the context of transplantation, and the analysis of endoplasmic reticulum stress in transplantation may reveal new pathways of regulation in long-term graft acceptance thereby increasing our understanding of tolerance.
Collapse
Affiliation(s)
- Maud Racapé
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 643 and Institut de Transplantation Urologie-Néphrologie, Nantes, France
- Université de Nantes, Nantes, France
| | - Jean-Paul Duong Van Huyen
- Institut National de la Santé Et de la Recherche Médicale U970, PARCC, Hôpital Européen Georges Pompidou, Université Paris Descartes, Paris, France
| | - Richard Danger
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 643 and Institut de Transplantation Urologie-Néphrologie, Nantes, France
- Université de Nantes, Nantes, France
| | - Magali Giral
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 643 and Institut de Transplantation Urologie-Néphrologie, Nantes, France
- Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France
| | - Françoise Bleicher
- Université de Lyon, Université Lyon 1, Institut de Génomique Fonctionnelle de Lyon, Unité Mixte de Recherche 5242 et Centre National de la Recherche Scientifique, Ecole Normale Supérieure de Lyon, Lyon, France
| | | | - Annaïck Pallier
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 643 and Institut de Transplantation Urologie-Néphrologie, Nantes, France
| | - Paul Pilet
- Faculté d'Odontologie, Institut National de la Santé Et de la Recherche Médicale EMI 9903, Nantes, France
| | | | - Joanna Ashton-Chess
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 643 and Institut de Transplantation Urologie-Néphrologie, Nantes, France
- Université de Nantes, Nantes, France
| | - Emilie Dugast
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 643 and Institut de Transplantation Urologie-Néphrologie, Nantes, France
- Université de Nantes, Nantes, France
| | - Ségolène Pettré
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 643 and Institut de Transplantation Urologie-Néphrologie, Nantes, France
- Université de Nantes, Nantes, France
| | - Béatrice Charreau
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 643 and Institut de Transplantation Urologie-Néphrologie, Nantes, France
- Université de Nantes, Nantes, France
- Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France
| | - Jean-Paul Soulillou
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 643 and Institut de Transplantation Urologie-Néphrologie, Nantes, France
- Université de Nantes, Nantes, France
- Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France
| | - Sophie Brouard
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 643 and Institut de Transplantation Urologie-Néphrologie, Nantes, France
- * E-mail:
| |
Collapse
|
34
|
Brouard S, Le Bars A, Dufay A, Gosselin M, Foucher Y, Guillet M, Cesbron-Gautier A, Thervet E, Legendre C, Dugast E, Pallier A, Guillot-Gueguen C, Lagoutte L, Evanno G, Giral M, Soulillou JP. Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl Int 2011; 24:536-47. [PMID: 21457359 DOI: 10.1111/j.1432-2277.2011.01251.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Despite their utility, immunosuppressive treatments have numerous side effects, including infectious complications, malignancies and metabolic disorders, all of which contribute to long-term graft loss. In addition to the development of new pharmaceutical products with reduced toxicity and more comfortable modes of administration, tailoring immunosuppression according to the immune status of each patient would represent a significant breakthrough. Gene expression profiling has been shown to be a clinically relevant monitoring tool. In this paper, we have assessed the overall long-term kidney transplant outcome and attempted to identify operationally tolerant-like patients among recipients with stable clinical status at least 5 years post-transplantation. We thus measured a combination of noninvasive blood biomarkers of operational tolerance in a cohort of 144 stable patients and showed that only 3.5% exhibited a gene expression profile of operational tolerance, suggesting that such a profile can be detected under immunosuppressive therapy but that its frequency is low in kidney transplant recipients when compared with liver transplant recipients. We suggest that a rational approach to patient selection, based on a combination of clinical and biological characteristics, may help to provide a safer method for identification of patients potentially suitable for immunosuppressive drug weaning procedures.
Collapse
Affiliation(s)
- Sophie Brouard
- Institut National de la Santé et de la Recherche Médicale, and Institut de Transplantation Urologie, Néphrologie, Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Ashton-Chess J, Dugast E, Colvin RB, Giral M, Foucher Y, Moreau A, Renaudin K, Braud C, Devys A, Brouard S, Soulillou JP. Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients. J Am Soc Nephrol 2009; 20:1113-22. [PMID: 19357258 DOI: 10.1681/asn.2008050450] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Animal studies have suggested a potential role for regulatory T cells (Tregs) in allograft tolerance, but these FOXP3+ cells seem to be an inherent component of acute rejection (AR) in human recipients of renal transplants. The balance between regulatory cells and effector/cytotoxic cells may determine graft outcome; this balance has not been described for chronic allograft injury. We investigated the expression of key regulatory, effector, and cytotoxic transcripts (i.e., FOXP3, T-bet, and granzyme B, respectively) in the grafts and peripheral blood of long-term-surviving renal transplant patients. We found that, whereas neither intragraft nor peripheral blood FOXP3 or T-bet mRNA could distinguish between rejection and nonrejection status, granzyme B (GrzB) mRNA could: It was significantly increased in the graft and significantly decreased in the peripheral blood of patients with chronic antibody-mediated rejection (CAMR). Quantifying peripheral blood GrzB mRNA demonstrated potential to aid in the noninvasive diagnosis of CAMR. In summary, these data affirm GrzB as a marker not only for AR but also for CAMR. In addition, we identified several previously unreported clinical or demographic factors influencing regulatory/effector/cytotoxic profiles in the peripheral blood, highlighting the necessity to consider confounding variables when considering the use of potential biomarkers, such as FOXP3, for diagnosis or prognosis in kidney transplantation.
Collapse
Affiliation(s)
- Joanna Ashton-Chess
- INSERM, U643, Institut de Transplantation et de Recherche en Transplantation, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Ashton-Chess J, Giral M, Mengel M, Renaudin K, Foucher Y, Gwinner W, Braud C, Dugast E, Quillard T, Thebault P, Chiffoleau E, Braudeau C, Charreau B, Soulillou JP, Brouard S. Tribbles-1 as a novel biomarker of chronic antibody-mediated rejection. J Am Soc Nephrol 2008; 19:1116-27. [PMID: 18369086 DOI: 10.1681/asn.2007101056] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Diagnosis of the specific cause of late allograft injury is necessary if more personalized and efficient immunosuppressive regimens are to be introduced. This study sought previously unrecognized biomarkers for specific histologic diagnoses of late graft scarring by comparison of gene sets from published microarray studies. Tribbles-1 (TRIB1), a human homolog of Drosophila tribbles, was identified to be a potentially informative biomarker. For testing this, mRNA expression in 76 graft biopsies, 71 blood samples, and 11 urine samples were profiled from independent cohorts of renal transplant patients with different histologic diagnoses recruited at two European centers. TRIB1 but not TRIB2 or TRIB3 was found to be a potential blood and tissue biomarker of chronic antibody-mediated rejection, an active immune-mediated form of chronic allograft failure associated with a poor prognosis. TRIB1 mRNA levels in peripheral blood mononuclear cells discriminated patients with chronic antibody-mediated rejection from those with other types of late allograft injury with high sensitivity and specificity. TRIB1 was also upregulated in a rodent model of chronic cardiac vasculopathy, suggesting that this biomarker may be useful in other solid-organ transplants and across species. It was determined that TRIB1 is expressed primarily by antigen-presenting cells and activated endothelial cells. Overall, these data support the potential use of TRIB1 as a biomarker of chronic antibody-mediated allograft failure.
Collapse
Affiliation(s)
- Joanna Ashton-Chess
- INSERM U643, Centre Hospitalier Universitaire Nantes, Institut de Transplantation et de Recherche en Transplantation, Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|